Please login to the form below

Not currently logged in

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

Kite PharmaKite Pharma has said it should be able to file for approval of its lead CAR-T candidate KTE-C19 in the US after it met its targets in a phase II trial.

Interim results from the ZUMA-1 study showed that the therapy achieved a 44% response rate, with 39% of patients with aggressive forms of non-Hodgkin's lymphoma (NHL) showing a complete response to the treatment after three months, despite having previously-failed chemotherapy.

The company says it intends to file for approval of KTE-C19 in three types of aggressive NHL - diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) - on the strength of the trial results.

The combined complete response rate represents nearly a five-fold increase from an 8% response rate seen in the SCHOLAR-1 study, which looked at historical data on treatments in a similar patient population, commented Jeff Wiezorek, Kite's senior vice president of clinical development.

News of the data caused Kite Pharma's shares to leap in after-hours trading and also pulled up other CAR-T players such as Juno Therapeutics, which have been a little volatile of late.

The positive data has gone a long way to calm investor nerves about CAR-T, an emerging technology that relies on the use of modified immune cells that are engineered to attack and destroy malignant cells.

Patient deaths in an earlier Juno trial - now attributed to a cytotoxic drug used to prime the patient for the therapy - gave shareholders some anxiety earlier this year. That has since been exacerbated by Novartis' decision to close a cell therapy unit working on CAR-T - despite assertions its development CAR-T programmes remain on track - as well as questions about the complexity of the manufacturing and treatment process.

"ZUMA-1 is the largest CAR-T study reported in NHL," said Wiezorek. "We were able to manufacture KTE-C19 for 99% of patients enrolled in the study, and successfully handle the study logistics and adverse event management at over 20 sites, most of which had no prior experience in CAR-T therapy."

The main analysis of 101 patients in ZUMA-1 will be carried out after approximately six months of follow-up and is expected in the first quarter of 2017. If the company can secure approval for KTE-C19 in its hoped-for timeframe it could leapfrog both Novartis and Juno and be the first to bring a CAR-T drug to market. 

Article by
Phil Taylor

27th September 2016

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....